Cancer medicine · 2026
Adjusted Risk Stratification of Indeterminate Thyroid Nodules Using the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Jessica, Abi-Raad Rita, Pai Sara I, Langdon Jonathan, Wang Minhua, Cai Guoping, Sinard John, Adeniran Adebowale J, Yu Sanhong
Аннотация
BACKGROUND: The TI-RADS guides the initial management of thyroid nodules, but the malignancy risk across different categories of cytologically indeterminate thyroid nodules (CITNs), particularly AUS and FN, remains unclear.
METHODS: We reviewed thyroid FNA specimens diagnosed as AUS or FN with TI-RADS scores of 3, 4, or 5 from 2017 to 2025. Clinical data, molecular results, and surgical outcomes were analyzed.
RESULTS: A total of 919 CITNs were identified: 304 with TI-RADS 3, 454 with TI-RADS 4, and 161 with TI-RADS 5. In the absence of molecular alterations, the risk of malignancy (ROM) was low for AUS and FN in both TI-RADS 3 and 4 categories (< 10%). In contrast, TI-RADS 5 nodules diagnosed as AUS or FN had the highest ROM (56%). ROM similarly increased with the TI-RADS score. For AUS, ROM was 14% (TI-RADS 3), 31% (TI-RADS 4), and 60% (TI-RADS 5). For FN, ROM increased from 26% to 44% to 57% across TI-RADS 3, 4, and 5, respectively. Notably, even AUS nodules without detectable mutations had a high ROM of 44% in TI-RADS 5, compared to 10% and 15% in TI-RADS 3 and 4, respectively.
CONCLUSION: Our findings demonstrate distinctive ROMs among AUS and FN stratified by TI-RADS category and underscore the variable utility of molecular testing. TI-RADS 5 CITNs carry a significantly higher ROM even in the absence of molecular alterations, suggesting the importance of combining TI-RADS and TBSRTC.
METHODS: We reviewed thyroid FNA specimens diagnosed as AUS or FN with TI-RADS scores of 3, 4, or 5 from 2017 to 2025. Clinical data, molecular results, and surgical outcomes were analyzed.
RESULTS: A total of 919 CITNs were identified: 304 with TI-RADS 3, 454 with TI-RADS 4, and 161 with TI-RADS 5. In the absence of molecular alterations, the risk of malignancy (ROM) was low for AUS and FN in both TI-RADS 3 and 4 categories (< 10%). In contrast, TI-RADS 5 nodules diagnosed as AUS or FN had the highest ROM (56%). ROM similarly increased with the TI-RADS score. For AUS, ROM was 14% (TI-RADS 3), 31% (TI-RADS 4), and 60% (TI-RADS 5). For FN, ROM increased from 26% to 44% to 57% across TI-RADS 3, 4, and 5, respectively. Notably, even AUS nodules without detectable mutations had a high ROM of 44% in TI-RADS 5, compared to 10% and 15% in TI-RADS 3 and 4, respectively.
CONCLUSION: Our findings demonstrate distinctive ROMs among AUS and FN stratified by TI-RADS category and underscore the variable utility of molecular testing. TI-RADS 5 CITNs carry a significantly higher ROM even in the absence of molecular alterations, suggesting the importance of combining TI-RADS and TBSRTC.